血清omentin-1和vaspin在非酒精性脂肪性肝病患者中的表达及意义

肝脏 ›› 2021, Vol. 26 ›› Issue (1): 67-70.

血清omentin-1和vaspin在非酒精性脂肪性肝病患者中的表达及意义

苏秀丽, 王同生, 张英剑

471000 洛阳河南科技大学第一附属医院(河南科技大学临床医学院)消化科

收稿日期:2019-11-20 出版日期:2021-01-31 发布日期:2021-02-26
通讯作者: 王同生,Email:wtsh730202@126.com
基金资助:
河南省医学科技攻关项目(201403146)

The expression and significance of serum omentin-1 and vaspin in nonalcoholic fatty liver disease

SU Xiu-li, WANG Tong-sheng, ZHANG Ying-jian

Department of Gastroenterology Diseases, the First Affiliated Hospital (Clinical Medical College) of Henan University of Science and Technology, Luoyang 471003, China

Received:2019-11-20 Online:2021-01-31 Published:2021-02-26
Contact: WANG Tong-sheng , Email:wtsh730202@126.com

摘要/Abstract

摘要： 目的探讨脂肪因子网膜蛋白-1(omentin-1)、内脏脂肪组织来源的丝氨酸蛋白酶抑制剂(visceral adipose tissue-derived serine protease inhibitor,vaspin)在非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)患者中的表达和意义,及其与白细胞介素-6(interleukin-6,IL-6)和C反应蛋白(creactive protein,CRP)的关系。方法 138例NAFLD患者(NAFLD组),B超检查证实脂肪肝,129例健康者作为对照组。均记录身高、体质量、腰围(WC),体质指数(BMI),检验血生化,及omentin-1、vaspin、IL-6和CRP水平。结果与对照组相比,NAFLD组的vaspin水平升高,omentin-1水平下降,IL-6、CRP水平增高(均P<0.05)。相关分析: vaspin水平分别与腰围、LDL-C、CRP、IL-6成正比(r值为0.231～0.341,均P<0.05);与HDL-C、omentin-1呈负相关(r值分别为-0.221,-0.246,均P<0.05)。血清omentin-1水平与腰围、CRP、IL-6呈负相关(r值为别-0.238～-0.319,均P<0.05),与HDL-C呈正相关(r=0.326,P<0.05)。Logistic 回归分析: omentin-1、vaspin、腰围、CRP、IL-6为患者发生NAFLD的独立相关因素[β值1.471～2.012,OR值(1.021～3.012),95％CI(1.431～4.979),均P<0.05]。结论 NAFLD患者omentin-1、vaspin、IL-6、CRP和健康组不同。Vaspin可能是NAFLD发生的预测因子,而omentin-1可能是预防NAFLD发生的保护性因子。其机制可能与炎症因子有关,具体机制需进一步研究。

关键词: 非酒精性脂肪性肝病, Omentin-1, Vaspin

Abstract: Objective To investigate the circulating levels of omentin1, visceral adipose tissue-derived serine protease inhibitor(vaspin) in NAFLD patients and to clarify their relationship with biochemical parameters, interleukin-6(IL-6), and C reactive protein(CRP).Methods One hundred and eight patients with NAFLD (NAFLD group), confirmed fatty liver by B-ultrasound, 129 healthy controls as control group. Height, weight, waist circumference, body mass index (BMI), blood biochemistry, serum CRP, IL-6, omentin-1, vaspin and apelin levels were recorded.Results Compared with the control group, the levels of serum vaspin in the NAFLD group were increased, the levels of omentin-1 were decreased, and the levels of IL-6 and CRP were increased. The difference was statistically significant (P<0.05). The vaspin levels were directly proportional to WC, LDL-C, CRP, and IL-6 (r values were 0.231 to 0.341, both P<0.05); negatively correlated with HDL-C and omentin-1 (r values were -0.221, -0.246, respectively, both P< 0.05). Serum omentin-1 levels were negatively correlated with WC, CRP and IL-6 (r value was -0.238 to -0.319, both P<0.05), and positively correlated with HDL-C (r=0.326, P<0.05). Logistic regression analysis showed that omentin-1, vaspin, waist circumference, CRP, IL-6 were independent factors related to NAFLD in patients [β values were 1.471-2.012, OR (1.021-3.012), 95% CI (1.431-4.779), both P< 0.05].Conclusion In patients with NAFLD, levels of omentin-1, vaspin, IL-6, and CRP were different from those in the healthy group. Vaspin may be predictors of NAFLD, and omentin-1 may be a protective factor against the development of NAFLD. Its mechanism may be related to inflammatory factors. The specific mechanism needs further study.

Key words: Nonalcoholic fatty liver disease, Omentin-1, Vaspin

苏秀丽, 王同生, 张英剑. 血清omentin-1和vaspin在非酒精性脂肪性肝病患者中的表达及意义[J]. 肝脏, 2021, 26(1): 67-70.

SU Xiu-li, WANG Tong-sheng, ZHANG Ying-jian. The expression and significance of serum omentin-1 and vaspin in nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2021, 26(1): 67-70.

参考文献

[1] Alexander KS, Zakai NA, Lidofsky SD, et al. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. PLoS One, 2018,13:e0194153.
[2] Feng R , Li Y , Wang C , et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract, 2014,106:88-94.
[3] Ebrahimi S , Gargari BP , Izadi A , et al. The effects of Ramadan fasting on serum concentrations of vaspin and omentin-1 in patients with nonalcoholic fatty liver disease. Eur J Integr Med,2018, 19:110-114.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志, 2011, 18:167-170.
[5] Byrne CD , Targher G . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia, 2017,60:1218-1222.
[6] Jung U , Choi MS . Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. Int J Mol Sci, 2014, 15:6184-6223.
[7] Zhong X , Li X , Liu F , et al. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem Biophys Res Commun, 2012, 425:401-406.
[8] Yilmaz Y , Yonal O , Kurt R , et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol, 2011, 54:S349-S350.
[9] Feng R , Li Y , Wang C , et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract, 2014, 106:88-94.
[10] Farhangi MA, Alipour B, Jafarvand E, et al. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch Med Res, 2014, 45:589-595.
[11] Salama HM , Ashraf G , Motawie AA , et al. Adipokines Vaspin and Visfatin in Obese Children. Open Access Maced J Med Sci, 2015, 3:563-566.
[12] Polyzos SA , Kountouras J , Polymerou V , et al. Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease. Ann Hepatol, 2016, 15:705.
[13] Yamawaki H , Kuramoto J , Kameshima S , et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun, 2011, 408:339-343.

[1]	冯少阳, 李广明, 苏航. 瞬时弹性成像对慢性乙型肝炎合并非酒精性脂肪性肝病患者肝纤维化的评估价值[J]. 肝脏, 2021, 26(1): 44-46.
[2]	季蕾, 范建高, 李锋. 男性酒精性和非酒精性脂肪性肝病患者代谢异常的比较[J]. 肝脏, 2021, 26(1): 60-63.
[3]	何美情, 韩磊, 彭健美, 高燕华, 任媛, 管湘平, 王娟. 实时剪切波弹性成像超声定量检测评估儿童脂肪肝的应用价值[J]. 肝脏, 2020, 25(9): 978-981.
[4]	徐梓馨, 罗昕, 罗声政, 徐铭益, 林仁坤. MicroRNA27a抑制肝星状细胞脂质代谢分子机制的初步研究[J]. 肝脏, 2020, 25(9): 994-997.
[5]	梁栋, 王瑞金, 王全楚. 健康人群无症状ALT升高及其与非酒精性脂肪性肝病的相关性分析[J]. 肝脏, 2020, 25(9): 998-999.
[6]	文琼花, 唐敏云, 魏玉. 血清25(OH)D判断糖尿病合并NAFLD患者继发进展性肝纤维化的应用价值[J]. 肝脏, 2020, 25(8): 810-812.
[7]	邓永红, 王璟, 王晓莉, 李文霞, 熊万春. 雄激素水平变化对多囊卵巢综合征伴非酒精性脂肪性肝病患者的影响[J]. 肝脏, 2020, 25(6): 622-624.
[8]	刘婕, 常毅娜, 曹书义. HIIT对NAFLD合并糖尿病的肥胖患者内脏脂质、胰岛素抵抗及健康相关生活质量的影响[J]. 肝脏, 2020, 25(4): 426-428.
[9]	宁惠明, 徐燕华. 非酒精性脂肪性肝病患者血清视黄醛结合蛋白4的变化及临床意义[J]. 肝脏, 2020, 25(4): 429-432.
[10]	徐建浩, 居峰, 章艳. 血清高分子量脂联素在非酒精性脂肪性肝病患者中的检测意义[J]. 肝脏, 2020, 25(12): 1313-1316.
[11]	张天柱, 刘文军, 陈玉军, 黄佩杰. MRI R₂^*值在非酒精性脂肪性肝病患者肝纤维化分期评估中的最佳阈值探讨[J]. 肝脏, 2020, 25(12): 1317-1319.
[12]	徐丹, 戴秀丽, 张晓梅, 郝咏梅. 2型糖尿病并发非酒精性脂肪性肝病患者血清趋化素、细胞角蛋白18 M30、细胞角蛋白18 M65水平及其临床意义[J]. 肝脏, 2020, 25(1): 46-49.
[13]	焦栓林, 秦建增, 杜世奇, 赵晓蕊, 张玉华, 欧阳洪, 胡艳玲. 双环醇联合水飞蓟宾治疗非酒精性脂肪性肝病疗效观察[J]. 肝脏, 2019, 24(9): 1068-1069.
[14]	龙柳艳, 韦晓谋. 非酒精性脂肪性肝病患者血清Betatrophin水平评估病情严重程度的应用价值[J]. 肝脏, 2019, 24(8): 933-935.
[15]	汤群, 欧强. PTX3在非酒精性脂肪肝患者血清中的表达及与肝纤维化评分的相关性[J]. 肝脏, 2019, 24(2): 175-177.